ClinicalTrials.gg
CompletedNCT05267054Updated Sep 15, 2025Results posted

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

A Phase 1/2 interventional study of Ociperlimab and Tislelizumab in Relapsed Diffuse Large B-cell Lymphoma and Refractory Diffuse Large B-cell Lymphoma, sponsored by BeiGene. Completed at 19 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by BeiGene · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
53
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Lymphoma, Large B-Cell, Diffuse by BeOne Medicines — 3 open to participants now, 3 under way, none of them phase 3. Lymphoma, Large B-Cell, Diffuse · BeOne Medicines.

Enrollment
7th of 10
53 · median 66
Started
2022
the only one that year
Phase 1/2
3 of 10
1 open now
Registered
7th of 10
by date

Among the 10 studies in Lymphoma, Large B-Cell, Diffuse by BeOne Medicines, this one is the 7th largest by enrollment, is the only one that started in 2022, is one of 3 in phase 1/2, and was the 7th registered.

Lymphoma, Large B-Cell, Diffuse

1,870 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

3 of the 10 studies in Lymphoma, Large B-Cell, Diffuse by BeOne Medicines are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Lymphoma, Large B-Cell, Diffuse by BeOne Medicines, or all of them as a file.
02

Study summary

The primary purpose of this study is to assess the safety and tolerability of ociperlimab (BGB-A1217) in combination with tislelizumab (BGB-A317) or rituximab in participants with relapsed or refractory (R/R) diffuse large B cell lymphoma (DLBCL)

03

Conditions studied

  • Relapsed Diffuse Large B-cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma

Keywords

  • Lymphoma
  • Tumor
  • Large B-cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed DLBCL NOS (Not Otherwise Specified), Epstein-Barr virus (EBV) + DLBCL NOS, or high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (double/triple-hit lymphoma [DHL/THL]), based on the World Health Organization (WHO) 2016 classification of tumors of hematopoietic and lymphoid tissue

    1. Cohort 1: participants must have positive tumor programmed cell death ligand-1 () immunohistochemistry (IHC) testing results as determined by local pathologist
    2. Cohort 2: Participants must have negative tumor PD-L1 IHC results as determined by a local pathologist in the dose confirmation stage. The dose expansion stage can enroll participants regardless of PD-L1 expression.
  2. Previously received ≥ 1 line of adequate systemic anti DLBCL therapy, defined as an anti CD20 antibody based chemoimmunotherapy for ≥ 2 consecutive cycles, unless participants had PD before Cycle 2.
  3. disease before study entry, defined as either:

    1. Recurrent disease after having achieved disease remission (complete response or partial response) during or at the completion of the latest treatment regimen.
    2. Stable disease or progressive disease (PD) at the completion of the latest treatment regimen.
  4. Ineligible for high dose therapy/hematopoietic stem cell transplantation
  5. as assessed by computed tomography (CT) or magnetic resonance imaging (MRI) and defined as at least 1 lymph node > 1.5 cm in the longest diameter and/or at least 1 extranodal lesion > 1.0 cm in the longest diameter, and measurable lesion (s) in 2 perpendicular diameters

Exclusion criteria

Exclusion Criteria:

  1. Current or history of central nervous system lymphoma
  2. Histologically transformed lymphoma
  3. Receipt of the following treatment:

    1. Systemic chemotherapy, targeted small molecule therapy or radiation therapy within 4 weeks (or 5 half lives, whichever is shorter) before first dose of study drug
    2. Recent treatment with another monoclonal antibody within 4 weeks before first dose of study drug
    3. treatment within 4 weeks (or 5 half lives, whichever is shorter) before first dose of study drug
    4. Treatment with stem cell transplantation within 6 months before first dose of study drug
    5. Treatment with allogeneic hematopoietic stem cell transplantation or organ transplantation
    6. Treatment with anti-programmed cell death protein-1 (), anti PD-L1, anti PD-L2, anti T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT), anti CTLA4 or other antibody or drug specifically targeting T cell costimulation or checkpoint pathways.
  4. Active diseases or history of autoimmune diseases that may relapse, with the following exceptions:

    1. Controlled Type 1 diabetes
    2. Hypothyroidism (provided that it is managed with hormone replacement therapy only)
    3. Controlled celiac disease
    4. Skin diseases not requiring systemic treatment (eg, vitiligo, psoriasis, or alopecia)
    5. Any other disease that is not expected to recur in the absence of external triggering factors

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Ociperlimab + Tislelizumab

    Participants received ociperlimab 900 mg and tislelizumab 200 mg every three weeks (Q3W) by intravenous injection (IV) until confirmed progressive disease, death, withdrawal of consent, loss of follow-up, or the end of study.

    Drug: Ociperlimab · Drug: Tislelizumab

  • Experimental
    Ociperlimab + Rituximab

    Participants received ociperlimab 900 mg and rituximab 375 mg/m² Q3W by intravenous injection until confirmed progressive disease, death, withdrawal of consent, loss of follow-up, or the end of study.

    Drug: Ociperlimab · Drug: Rituximab

Interventions

  • administered intravenously

    Also known as: BGB-A1217

  • Administered intravenously once every 3 weeks

    Also known as: BGB-A317, Tevimbra

  • Administered intravenously once every 3 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug(s), whether considered related to study drug(s) or not. An SAE is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator based on medical judgement (eg, may jeopardize the patient or may require medical/surgical intervention to prevent one of the outcomes listed above).

    Time frame: From first dose of study drug up to 30 days after last dose, maximum time on treatment was 98 weeks.

  2. Recommended Phase 2 Dose (RP2D) of Ociperlimab When Administered in Combination With Tislelizumab or Rituximab

    The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 33.3%

    Time frame: 21 days

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants who achieved a best overall response of partial response (PR) or complete response (CR) based on the Lugano classification as assessed by the investigator. Response was evaluated using computed tomography (CT) and metabolic imaging (fluorodeoxyglucose-positron emission tomography (FDGPET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). PR is partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions.

    Time frame: From first dose of study drug to the data cutoff date of 30 August 2024; maximum time on study was 28 months.

  2. Complete Response Rate (CRR)

    CRR is defined as the percentage of participants who achieved a complete response per the Lugano Classification (2014) as assessed by the investigator.

    Time frame: From first dose of study drug to the data cutoff date of 30 August 2024; maximum time on study was 28 months.

  3. Duration of Response (DOR)

    DOR is defined as the time from the date that response criteria were first met to the date that progressive disease is objectively documented per Lugano Classification (2014), as assessed by the investigator, or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method.

    Time frame: Up to the data cutoff date of 30 August 2024; maximum time on study was 28 months.

  4. Time to Response (TTR)

    TTR is defined as the time from study treatment start to date of the earliest qualifying response (partial response or better) per Lugano Classification (2014) as assessed by the investigator

    Time frame: From first dose of study drug to the data cutoff date of 30 August 2024; maximum time on study was 28 months.

  5. Progression-free Survival (PFS)

    PFS is defined as the time from first dose until first documentation of progression per Lugano Classification (2014), as assessed by the investigator, or death, whichever comes first. Median PFS was estimated using the Kaplan-Meier method.

    Time frame: From first dose of study drug to the data cutoff date of 30 August 2024; maximum time on study was 28 months.

  6. Overall Survival (OS)

    OS is defined as the time from first study drug administration to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.

    Time frame: From first dose of study drug to the data cutoff date of 30 August 2024; maximum time on study was 28 months.

  7. Serum Concentration of Ociperlimab

    Time frame: Predose and end of infusion (EOI) on Cycle 1 Day 1 (C1D1), Cycle 2 Day 1, Cycle 5 Day 1, Cycle 9 Day 1, and Cycle 17 Day 1

  8. Host Immunogenicity: Number of Participants With Anti-drug Antibodies (ADA) to Ociperlimab

    The number of participants with anti-drug antibodies to ociperlimab includes participants that were ADA-negative at Baseline and ADA-positive after drug administration during the treatment or follow-up observation period and participants who were positive at Baseline for ADA and with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period.

    Time frame: From first dose of study treatment to 30 days after last dose; maximum time on treatment was 98 weeks

07

Results

Posted Sep 15, 2025

Participant flow

The study began in April 2022 and completed in August 2024. Fifty-three participants were enrolled in this study, and all received treatment.

Participant flow — Overall Study
MilestoneOciperlimab + TislelizumabOciperlimab + Rituximab
Started2429
Completed00
Not completed2429
Withdrew: Death1314
Withdrew: Study ended by sponsor913
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug(s), whether considered related to study drug(s) or not. An SAE is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator based on medical judgement (eg, may jeopardize the patient or may require medical/surgical intervention to prevent one of the outcomes listed above).

Time frame:
From first dose of study drug up to 30 days after last dose, maximum time on treatment was 98 weeks.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsOciperlimab + TislelizumabOciperlimab + Rituximab
Treatment Emergent Adverse Events2428
Serious Adverse Events98
PrimaryRecommended Phase 2 Dose (RP2D) of Ociperlimab When Administered in Combination With Tislelizumab or Rituximab

The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 33.3%

Time frame:
21 days
Reported as:
Number · mg Q3W
Recommended Phase 2 Dose (RP2D) of Ociperlimab When Administered in Combination With Tislelizumab or Rituximab
mg Q3WOciperlimab + TislelizumabOciperlimab + Rituximab
Recommended Phase 2 Dose (RP2D) of Ociperlimab When Administered in Combination With Tislelizumab or Rituximab900900
SecondaryOverall Response Rate (ORR)

ORR is defined as the percentage of participants who achieved a best overall response of partial response (PR) or complete response (CR) based on the Lugano classification as assessed by the investigator. Response was evaluated using computed tomography (CT) and metabolic imaging (fluorodeoxyglucose-positron emission tomography (FDGPET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). PR is partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions.

Time frame:
From first dose of study drug to the data cutoff date of 30 August 2024; maximum time on study was 28 months.
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsOciperlimab + TislelizumabOciperlimab + Rituximab
Overall Response Rate (ORR)17.4 (5.0 to 38.8)18.5 (6.3 to 38.1)
SecondaryComplete Response Rate (CRR)

CRR is defined as the percentage of participants who achieved a complete response per the Lugano Classification (2014) as assessed by the investigator.

Time frame:
From first dose of study drug to the data cutoff date of 30 August 2024; maximum time on study was 28 months.
Reported as:
Number · percentage of participants
Complete Response Rate (CRR)
percentage of participantsOciperlimab + TislelizumabOciperlimab + Rituximab
Complete Response Rate (CRR)13.0 (2.8 to 33.6)7.4 (0.9 to 24.3)
SecondaryDuration of Response (DOR)

DOR is defined as the time from the date that response criteria were first met to the date that progressive disease is objectively documented per Lugano Classification (2014), as assessed by the investigator, or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method.

Time frame:
Up to the data cutoff date of 30 August 2024; maximum time on study was 28 months.
Reported as:
Median · Months
Duration of Response (DOR)
MonthsOciperlimab + TislelizumabOciperlimab + Rituximab
Duration of Response (DOR)13.34 (6.2 to 18.7)7.82 (0.0 to 8.5)
SecondaryTime to Response (TTR)

TTR is defined as the time from study treatment start to date of the earliest qualifying response (partial response or better) per Lugano Classification (2014) as assessed by the investigator

Time frame:
From first dose of study drug to the data cutoff date of 30 August 2024; maximum time on study was 28 months.
Reported as:
Median · months
Time to Response (TTR)
monthsOciperlimab + TislelizumabOciperlimab + Rituximab
Time to Response (TTR)2.09 (2.07 to 2.17)2.04 (1.97 to 2.40)
SecondaryProgression-free Survival (PFS)

PFS is defined as the time from first dose until first documentation of progression per Lugano Classification (2014), as assessed by the investigator, or death, whichever comes first. Median PFS was estimated using the Kaplan-Meier method.

Time frame:
From first dose of study drug to the data cutoff date of 30 August 2024; maximum time on study was 28 months.
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsOciperlimab + TislelizumabOciperlimab + Rituximab
Progression-free Survival (PFS)1.2 (0.9 to 1.9)1.8 (0.9 to 2.2)
SecondaryOverall Survival (OS)

OS is defined as the time from first study drug administration to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.

Time frame:
From first dose of study drug to the data cutoff date of 30 August 2024; maximum time on study was 28 months.
Reported as:
Median · Months
Overall Survival (OS)
MonthsOciperlimab + TislelizumabOciperlimab + Rituximab
Overall Survival (OS)13.2 (4.4 to NA)13.3 (4.9 to NA)
SecondarySerum Concentration of Ociperlimab
Time frame:
Predose and end of infusion (EOI) on Cycle 1 Day 1 (C1D1), Cycle 2 Day 1, Cycle 5 Day 1, Cycle 9 Day 1, and Cycle 17 Day 1
Reported as:
Geometric mean · μg/mL
Serum Concentration of Ociperlimab
μg/mLOciperlimab + TislelizumabOciperlimab + Rituximab
Predose C1D1NA ± NANA ± NA
EOI C1D1323.96 ± 21.810296.48 ± 18.832
Predose C2D161.84 ± 36.83263.68 ± 38.413
EOI C2D1371.62 ± 24.589389.27 ± 18.555
Predose C5D1127.20 ± 45.138184.09 ± 27.675
EOI C5D1450.52 ± 10.707507.48 ± 15.295
Predose C9D1181.58 ± 46.927184.83 ± 23.101
Predose C17D1320.00—
SecondaryHost Immunogenicity: Number of Participants With Anti-drug Antibodies (ADA) to Ociperlimab

The number of participants with anti-drug antibodies to ociperlimab includes participants that were ADA-negative at Baseline and ADA-positive after drug administration during the treatment or follow-up observation period and participants who were positive at Baseline for ADA and with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period.

Time frame:
From first dose of study treatment to 30 days after last dose; maximum time on treatment was 98 weeks
Reported as:
Count of participants · Participants
Host Immunogenicity: Number of Participants With Anti-drug Antibodies (ADA) to Ociperlimab
ParticipantsOciperlimab + TislelizumabOciperlimab + Rituximab
Host Immunogenicity: Number of Participants With Anti-drug Antibodies (ADA) to Ociperlimab01

Adverse events

Collected over All-cause mortality was assessed from enrollment through the end of the study, maximum time on study was 28 months. Adverse events were assessed from first dose of study treatment to 30 days after last dose; maximum time on treatment was 98 weeks.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ociperlimab + Tislelizumab13/24 (54.2%)9/24 (37.5%)23/24 (95.8%)
Ociperlimab + Rituximab14/29 (48.3%)8/29 (27.6%)28/29 (96.6%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventOciperlimab + TislelizumabOciperlimab + Rituximab
Febrile neutropeniaBlood and lymphatic system disorders1/240/29
ConstipationGastrointestinal disorders1/240/29
DeathGeneral disorders1/240/29
Oedema peripheralGeneral disorders1/240/29
BacteraemiaInfections and infestations1/240/29
Herpes zosterInfections and infestations1/240/29
Oral infectionInfections and infestations1/240/29
Neutrophil count decreasedInvestigations1/241/29
ShockVascular disorders1/240/29
AnaemiaBlood and lymphatic system disorders0/241/29
Most frequent other events
Showing 10 of 129
Most frequent other events
EventOciperlimab + TislelizumabOciperlimab + Rituximab
Neutrophil count decreasedInvestigations7/249/29
White blood cell count decreasedInvestigations7/247/29
AnaemiaBlood and lymphatic system disorders4/248/29
Lymphocyte count decreasedInvestigations6/245/29
Platelet count decreasedInvestigations1/247/29
Blood lactate dehydrogenase increasedInvestigations5/246/29
HyperuricaemiaMetabolism and nutrition disorders1/246/29
RashSkin and subcutaneous tissue disorders1/246/29
PyrexiaGeneral disorders4/244/29
HypokalaemiaMetabolism and nutrition disorders4/243/29

Baseline characteristics

Safety Analysis Set

Age, Continuous
Age, Continuous(Years)Ociperlimab + TislelizumabOciperlimab + RituximabTotal
Median64.0 (40 to 79)66.0 (21 to 80)65.0 (21 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)Ociperlimab + TislelizumabOciperlimab + RituximabTotal
Female141327
Male101626
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ociperlimab + TislelizumabOciperlimab + RituximabTotal
Asian242953
Region of Enrollment
Region of Enrollment(participants)Ociperlimab + TislelizumabOciperlimab + RituximabTotal
China242953
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Ociperlimab + TislelizumabOciperlimab + RituximabTotal
Grade 08816
Grade 1162137
Grade 2000
Weight
Weight(kg)Ociperlimab + TislelizumabOciperlimab + RituximabTotal
Median59.00 (45.5 to 102.0)63.80 (45.0 to 90.0)62.00 (45.0 to 102.0)
08

Study locations

19 sites
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing Municipality 100050, China
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
  • Beijing Hospital
    Beijing, Beijing Municipality 100730, China
  • Zhujiang Hospital of Southern Medical University
    Guangzhou, Guangdong 510000, China
  • Sun Yat Sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Guangdong Provincial Peoples Hospital
    Guangzhou, Guangdong 510080, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • The First Affiliated Hospital of Nanchang University Branch Donghu
    Nanchang, Jiangxi 330006, China
  • Jiangxi Province Cancer Hospital
    Nanchang, Jiangxi 330029, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning 110004, China
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
  • Affiliated Zhongshan Hospital of Fudan University
    Shanghai, Shanghai Municipality 200032, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
    Chengdu, Sichuan 610071, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality 300060, China
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310016, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beigene.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Aug 2024, 28 months.

Results were first posted in Sep 2025, 1 year after primary completion.

Of 51 industry-sponsored phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 99. This study's 28 months is below that.

Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2022
First posted
Mar 4, 2022
StartActual
Apr 25, 2022
Primary completionActual
Aug 30, 2024
CompletionActual
Aug 30, 2024
Results first posted
Sep 15, 2025
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05267054
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Mar 4, 2022
Start date
Apr 25, 2022
Primary completion
Aug 30, 2024
Completion
Aug 30, 2024
Results posted
Sep 15, 2025
Last update
Sep 15, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion